Skip to content
Peptide Atlas
All peptides

Afamelanotide

Tier 1 · Human trials
Also known as Scenesse · Melanotan-1 · CUV1647 · Melanotan I

Supported by Tier 1 human randomized controlled trials (two pivotal parallel-group EPP trials, phase III CUV039) and FDA/EMA regulatory data, complemented by human observational studies, animal preclinical toxicology/PK work, and tier-3 expert-opinion reviews. Efficacy beyond EPP (vitiligo, acne, Hailey-Hailey, solar urticaria, polymorphic light eruption, acute ischemic stroke) rests on smaller or lower-tier studies. Several caveats apply: sources disagree on liver-damage protection, reported half-life, and RCT photosensitivity outcomes.

Half-life
~15 h
Routes
Subcutaneous controlled-release implant
Goals
Photoprotection · Skin pigmentation · Dermatologic disease management · Rare disease (EPP) symptom management
Cost / mg
Not recorded

How it works

Afamelanotide is a lab-made, longer-lasting version of a natural hormone (α-MSH) that tells pigment cells in the skin to make more of the dark protective pigment eumelanin. It does this by switching on the melanocortin-1 receptor (MC1R). The extra pigment builds up in the skin even without sun exposure, acting like a built-in sunscreen that reduces how much light penetrates. It also appears to boost the skin's antioxidant and DNA-repair defenses and to calm inflammation. In people with erythropoietic protoporphyria (EPP), this lets them tolerate more light and spend more pain-free time in sunlight.

Overview

Overview

Afamelanotide (brand name Scenesse; also known as Melanotan-1, CUV1647, and Melanotan I) is a synthetic tridecapeptide (13-amino-acid peptide) that is structurally analogous to endogenous α-melanocyte-stimulating hormone (α-MSH). It functions as a first-in-class melanocortin-1 receptor (MC1R) agonist.

The molecule was developed in the early 1980s by Victor Hruby and Mac Hadley's group at the University of Arizona. A foundational 1980 paper by Sawyer and colleagues described a synthetic α-MSH analogue with two substitutions — norleucine replacing methionine at position 4 and D-phenylalanine replacing L-phenylalanine at position 7 — which confers protease resistance and greater potency than the natural hormone. Its chemical formula is C78H111N21O19 with a molar mass of 1646.874 g/mol.

Mechanism of Action

By selectively binding and activating MC1R on melanocytes, afamelanotide triggers adenylyl cyclase, raises intracellular cyclic AMP, and activates the MITF pathway, driving expression of tyrosinase and related melanogenic enzymes. The result is increased synthesis of eumelanin and epidermal hyperpigmentation that occurs independently of exposure to sunlight or artificial UV light, increasing skin pigmentation to reduce light penetration. MC1R activation also upregulates nucleotide excision repair enzymes and antioxidant pathways, and afamelanotide exhibits dual photoprotective and anti-inflammatory effects.

Approved Indication

Afamelanotide is approved to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP) — a rare inherited disorder (estimated prevalence 1:75,000 to 1:180,000 in Europe) that presents with painful photosensitivity from early childhood due to protoporphyrin accumulation. It is the first effective approved medical treatment for EPP and received FDA orphan drug designation. The EMA recommended approval in December 2014 (approved in the EU in 2014 for prevention of phototoxicity in adults with EPP), and the FDA approved it in October 2019 for adults with EPP. It is the only FDA-approved drug in the Melanotan class. As of April 2026, there is no indication for cosmetic tanning; afamelanotide is available only as a prescription-only subcutaneous implant through licensed prescribers for the approved EPP indication.

Clinical Evidence

Efficacy was established in two parallel-group pivotal trials in EPP patients receiving an implant or placebo every two months:

  • U.S. study (94 patients, 270-day period): median pain-free time after 6 months was longer with afamelanotide (69.4 hours vs. 40.8 hours placebo; P=0.04).
  • EU study (74 patients, 180-day period): median pain-free time after 9 months was longer with afamelanotide (6.0 hours vs. 0.8 hours placebo; P=0.005), with fewer phototoxic reactions (77 vs. 146; P=0.04).

Quality of life improved in both pivotal trials. The phase III trial CUV039 showed improved light tolerance, more pain-free time in direct sunlight, and increased time to first phototoxicity symptoms under a standardized light source. Observational data (including a three-year study) support increased phototoxic burn tolerance time and quality of life, and better sunlight tolerance in EPP and X-linked protoporphyria (XLP).

It is worth noting that RCT results on photosensitivity have been inconsistent: within one review of three RCTs, one found roughly 8 additional pain-free sunlight minutes per day, another found no difference versus placebo, and another reported increased sun exposure with treatment. Some experts assert afamelanotide is more effective in clinical practice than in trials — an expert-opinion view.

Investigational and Off-Label Uses

Randomized controlled trial evidence supports use in polymorphic light eruption and vitiligo, and smaller studies demonstrated efficacy in acne vulgaris, Hailey-Hailey disease, and solar urticaria. Afamelanotide has been reviewed as a therapeutic option for vitiligo (alongside phototherapy, cyclosporine, PDE4 inhibitors, and JAK inhibitors), though no fully effective vitiligo treatment currently exists, and proposed for acne vulgaris (a synergistic mode of action attenuating Akt/mTORC1 and enhancing p53 signaling has been proposed). A single small observational study in acute ischemic stroke found it well tolerated and safe with apparent good recovery and radiological improvement. The broader melanocortin system is considered a promising target for metabolic disorders (obesity, cachexia) and anorexia nervosa. Larger studies are needed to confirm efficacy beyond EPP, and pediatric safety, efficacy, and optimal dosing data are lacking.

Liver Damage — A Contested Effect

Sources disagree on whether afamelanotide protects against EPP-related liver damage. One review reports a dose-dependent protective effect against EPP-related liver damage, supported by animal-model evidence that melanocyte-stimulating hormones protect the liver from injury. Another review holds it is only a symptomatic treatment — protoporphyrin IX (PPIX) levels remain unchanged, making it unlikely to protect against PPIX-mediated liver damage.

What the research shows

182 findings extracted from the 25 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 14 human trial findings, 11 human study findings and 6 expert opinion findings.

  • human trialOne RCT found a decrease in reported as well as measured photosensitivity by afamelanotide with an estimated difference between afamelanotide and placebo of 8 additionally minutes direct sunlight exposure per day without pain2

  • human trialAnother RCT found no difference in reported photosensitivity or sun habits between afamelanotide and placebo group2

  • human trialThe last RCT reported increased sun exposure while receiving afamelanotide2

  • human trialIn the U.S. study, the duration of pain-free time after 6 months was longer in the afamelanotide group (median, 69.4 hours, vs. 40.8 hours in the placebo group; P=0.04)5

  • human trialIn the European Union study, the duration of pain-free time after 9 months was longer in the afamelanotide group than in the placebo group (median, 6.0 hours vs. 0.8 hours; P=0.005)5

  • human trialIn the European Union study, the number of phototoxic reactions was lower in the afamelanotide group (77 vs. 146, P=0.04)5

  • human trialQuality of life improved with afamelanotide therapy in both trials5

  • human trialThe efficacy of SCENESSE was established in two parallel group clinical trials with patients with erythropoietic protoporphyria who received SCENESSE or placebo form of the implant subcutaneously every two months8

Show the remaining 23

  • human trialThe pivotal 2015 New England Journal of Medicine RCT found EPP patients on afamelanotide accumulated a median 69.4 pain-free hours in direct sunlight versus 40.8 hours on placebo12

  • human trialRandomized controlled trial evidence for successful use in polymorphic light eruption15

  • human trialRandomized controlled trial evidence for successful use in vitiligo15

  • human trialIn the phase III trial CUV039, afamelanotide treatment improved light tolerance in patients with EPP18

  • human trialAfamelanotide treatment enabled patients to spend more time in direct sunlight without pain compared with placebo18

  • human trialAfamelanotide increased the time to the appearance of the first symptoms of phototoxicity provoked by a standardized light source compared with placebo18

  • human studyAfamelanotide appears to be associated with good recovery and radiological improvement in AIS patients1

  • human studyA three-year observational study showed that afamelanotide increased phototoxic burn tolerance time and quality of life in EPP patients2

  • human studyOne observational study measured sun habits among a total of 26 patients with EPP who themselves had chosen to be on or off treatment with afamelanotide and found patients on treatment were more exposed to visible light than patients off treatment2

  • human studyAfamelanotide is associated with dose-dependent protective effect from liver damage related to erythropoietic protoporphyria7

  • human studyAfamelanotide administered subcutaneously improved tolerance to artificial white light in EPP patients13

  • human studyAfamelanotide administered subcutaneously increased pain-free time spent in direct sunlight in EPP patients13

  • human studySmaller studies demonstrated efficacy in treating acne vulgaris15

  • human studySmaller studies demonstrated efficacy in treating Hailey-Hailey disease15

  • human studySmaller studies demonstrated efficacy in treating solar urticaria15

  • human studyAfamelanotide is associated with better sunlight tolerance in patients with EPP and XLP17

  • human studyClinical studies in EPP showed that afamelanotide treatment significantly increased exposure to sunlight and quality of life22

  • expert opinionAfamelanotide could improve biological efficacy to attenuate UV-induced skin damage2

  • expert opinionExperts recommend afamelanotide for prevention of phototoxic symptoms in erythropoietic protoporphyria4

  • expert opinionMultiple therapeutic alternatives exist for vitiligo but there is currently no fully effective treatment for this disease14

  • expert opinionTreatment modalities like Janus kinase inhibitors, prostaglandin analogues, antioxidants, TNF-α inhibitors, targeted phototherapy, and excimer lasers has revolutionized the therapeutic possibilities for vitiligo19

  • expert opinionAfamelanotide was approved by the FDA in 2019 for the treatment of erythropoietic protoporphyria-associated phototoxicity20

  • expert opinionAfamelanotide treatment in clinical practice is much more effective than demonstrated in clinical trials22

How it works

Based on 9 human trial findings, 3 human study findings, 1 animal finding, 19 expert opinion findings and 4 theoretical findings.

  • human trialAfamelanotide is a melanocortin 1 receptor (MC1 receptor) agonist3

  • human trialAfamelanotide is a synthetic peptide and analogue of α-melanocyte stimulating hormone3

  • human trialAfamelanotide is an α-melanocyte–stimulating hormone analogue5

  • human trialAfamelanotide increases production of eumelanin in the skin independently of exposure to sunlight or artificial UV light sources8

  • human trialMay induce darkening of pre-existing nevi and ephelides due to its pharmacological effect10

  • human trialAfamelanotide is a synthetic, protease-resistant analog of alpha-melanocyte-stimulating hormone (α-MSH) that selectively binds the MC1R receptor to stimulate eumelanin production and photoprotection12

  • human trialMC1R activation triggers adenylyl cyclase, raises intracellular cyclic AMP (cAMP), and activates the MITF (microphthalmia-associated transcription factor) pathway, which drives expression of tyrosinase and related enzymes involved in eumelanin synthesis12

  • human trialMC1R activation upregulates nucleotide excision repair enzymes and antioxidant pathways, suggesting the receptor has photoprotective function12

Show the remaining 28

  • human trialAfamelanotide is a synthetic α-melanocyte stimulating hormone analogue and first-in-class melanocortin-1 receptor agonist18

  • human studyAfamelanotide induces the synthesis of melanin and eumelanin, leading to epidermal hyperpigmentation2

  • human studyAfamelanotide has antioxidant and anti-inflammatory activity2

  • human studyAfamelanotide is an analogue of alfa-melanocyte-stimulating hormone that increases the pigmentation of epidermis to reduce light penetration2

  • animalIn animal models, melanocyte-stimulating hormones (MSHs) protect the liver from various injuries7

  • expert opinionAfamelanotide is a derivative of alpha-melanocyte-stimulating hormone that acts as a melanocortin receptor agonist2

  • expert opinionAfamelanotide increases eumelanin production in the skin2

  • expert opinionAfamelanotide is a synthetic 13-amino acid peptide analog of the endogenous alpha melanocyte-stimulating hormone (α-MSH)2

  • expert opinionAfamelanotide is a melanocyte-stimulating hormone (MSH) analog6

  • expert opinionAfamelanotide is a melanocortin receptor agonist and binds predominantly to MC1-R8

  • expert opinionA foundational 1980 paper by Sawyer and colleagues described a synthetic analog with two substitutions at positions 4 and 7 of the α-MSH sequence — a norleucine replacing methionine at position 4, and a D-phenylalanine replacing L-phenylalanine at position 712

  • expert opinionAfamelanotide is a synthetic alpha melanocyte stimulating hormone presenting a higher activity than natural hormones13

  • expert opinionMain properties are related to the enhanced production of eumelanin by agonistically binding to the melanocortin-1 receptor13

  • expert opinionAfamelanotide is a synthetic analogue of α-melanocyte-stimulating hormone15

  • expert opinionDual photoprotective and anti-inflammatory effects15

  • expert opinionMultiple factors contribute to the loss of melanocytes in the skin, like oxidative stress, inflammation, genetics, and autoimmunity19

  • expert opinionAfamelanotide functions as a peptide drug targeting melanocortin receptors20

  • expert opinionMultiple factors contribute to melanocyte loss: metabolic abnormalities, oxidative stress, inflammation, and autoimmunity21

  • expert opinionA convergence theory was proposed that combines all existing theories into a comprehensive one in which several mechanisms contribute to the reduction of melanocyte viability21

  • expert opinionAfamelanotide is an α-melanocyte-stimulating hormone analog22

  • expert opinionAfamelanotide can activate eumelanogenesis without exposure to UV radiation22

  • expert opinionAfamelanotide acts on melanocortin-1 receptors22

  • expert opinionAfamelanotide has a synergistic mode of action involving attenuation of Akt/mTORC1 signaling and enhancement of p53 signal transduction23

  • expert opinionHomogenous pigmentation can be induced by α-melanocyte-stimulating hormone (MSH) homologues24

  • theoreticalSynthetic tridecapeptide and structural analog of α-melanocyte stimulating hormone (α-MSH)4

  • theoreticalIncreases skin production of eumelanin independently of exposure to sunlight or artificial ultraviolet light4

  • theoreticalAfamelanotide is a melanocortin-1 receptor (MC1-R) agonist11

  • theoreticalAfamelanotide increases production of eumelanin in the skin independent of exposure to sunlight or artificial light sources11

Dosing

Based on 12 human trial findings and 2 expert opinion findings.

  • human trialAfamelanotide is administered as subcutaneous implant3

  • human trialSubcutaneous implants containing 16 mg of afamelanotide were administered every 60 days5

  • human trialThe approved recommended dosage of SCENESSE is a single implant, containing 16 mg of afamelanotide, inserted subcutaneously above the anterior supra-iliac crest every 2 months8

  • human trialA single implant contains 16 mg of afamelanotide9

  • human trialSCENESSE should be administered subcutaneously every 2 months9

  • human trialImplant is inserted subcutaneously above the anterior supra-iliac crest9

  • human trialImplant: 16 mg of afamelanotide10

  • human trialInsert a single SCENESSE implant subcutaneously above the anterior supra-iliac crest every 2 months10

Show the remaining 6

  • human trialDosage is 16 mg implanted SC q2Months11

  • human trialAfamelanotide is available only as an FDA-approved prescription-only subcutaneous implant through licensed prescribers in the US for the approved EPP indication12

  • human trialAfamelanotide administered as a subcutaneous implant every 2 months16

  • human trialAdministered subcutaneously as a biodegradable, controlled-release implant18

  • expert opinionAfamelanotide is administered as a 16 mg implant every two months for patients with erythropoietic protoporphyria (EPP)2

  • expert opinionThe 60-day interval period was not based on effectiveness studies22

How the body handles it

Based on 5 human trial findings, 7 human study findings, 1 animal finding and 1 expert opinion finding.

  • human trialFollowing administration of a single subcutaneous implant of SCENESSE, the mean ± SD Cmax and AUC0-inf of afamelanotide were 3.7 ± 1.3 ng/mL and 138.9 ± 42.6 hr·ng/mL, respectively8

  • human trialHigh variability was observed in the plasma concentrations of afamelanotide8

  • human trialThe last measurable afamelanotide concentration is at 96 hours post-dose in most subjects studied8

  • human trialThe median Tmax is 36 hours8

  • human trialThe apparent half-life of afamelanotide is approximately 15 hours when administered subcutaneously in a controlled release implant8

  • human studyPeak plasma concentrations attained a median of 36 hours post-implantation4

  • human studyFollowing a single sub-Q implantation, last measurable plasma concentrations observed 96 hours post-dose in the majority of patients4

  • human studyHalf-life approximately 15 hours4

Show the remaining 6

  • human studyPeak plasma time is 36 hr11

  • human studyPeak plasma concentration is 3.7 ng/mL11

  • human studyAUC is 42.6 hr⋅ng/mL11

  • human studyHalf-life is 15 hr11

  • animalA 30-day Pharmacokinetic Study of Release of CUV1647 From 10- and 16-mg Bioresorbable Implants in Rats16

  • expert opinionAfamelanotide may undergo hydrolysis. However, its metabolic profile has not been fully characterized8

Safety and side effects

Based on 18 human trial findings, 15 human study findings, 9 animal findings and 6 expert opinion findings.

  • human trialThe most common reported adverse effects were nausea (19%), headache (20%), and implant site reactions (21%)3

  • human trialUncommon but potentially serious hypersensitivity reactions including anaphylaxis were also reported3

  • human trialAfamelanotide was found to sometimes induce darkening of certain pre-existing skin conditions3

  • human trialRegular full body skin examinations every 6 months is often recommended3

  • human trialOther common adverse effects reported during the clinical trials include back pain, upper respiratory tract infections, melanocyte naevus, decreased appetite, migraine, dizziness, weakness3

  • human trialAdverse events were mostly mild; serious adverse events were not thought to be related to the study drug5

  • human trialThe most common adverse reactions (incidence > 2%) are implant site reaction, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus, respiratory tract infection, non-acute porphyria, and skin irritation8

  • human trialSCENESSE may induce skin darkening, and a full body skin examination is recommended for patients twice a year8

Show the remaining 40

  • human trialSCENESSE may induce darkening of pre-existing nevi and ephelides due to its pharmacological effect9

  • human trialA regular full body skin examination (twice yearly) is recommended to monitor all nevi and other skin abnormalities9

  • human trialThe most common adverse reactions (incidence > 2%) are implant site reaction, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus, respiratory tract infection, non-acute porphyria, and skin irritation9

  • human trialA full body skin examination (twice yearly) is recommended to monitor pre-existing nevi and new skin pigmentary lesions10

  • human trialSerious hypersensitivity reactions, including anaphylaxis, have been reported10

  • human trialThe most common adverse reactions (incidence > 2%) are implant site reaction, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus, respiratory tract infection, non-acute porphyria, and skin irritation10

  • human trialNo serious adverse effects with afamelanotide use have been reported15

  • human trialDiffuse hyperpigmentation is experienced by almost all patients15

  • human trialAfamelanotide was generally well tolerated with no drug-related serious adverse events reported in the phase III trial18

  • human trialCommonly occurring adverse reactions included headache and implant-site reactions18

  • human studyAfamelanotide was well tolerated and safe in our small sample of AIS patients1

  • human studyThe most common adverse effects observed in clinical studies were nausea (19%), headache (20%), and implant site reactions, including discoloration, pain, hematoma or erythema (21%)2

  • human studyAfamelanotide can cause generalized increased skin pigmentation and darkening of pre-existing nevi and ephelides4

  • human studyMost common adverse effects (>2%) include implant site reaction, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus, respiratory tract infection, non-acute porphyria, skin irritation4

  • human studyImplant site reaction occurs in 21% of patients11

  • human studyNausea occurs in 19% of patients11

  • human studyOropharyngeal pain occurs in 7% of patients11

  • human studyFatigue occurs in 6% of patients11

  • human studySkin hyperpigmentation occurs in 4% of patients11

  • human studyDizziness occurs in 4% of patients11

  • human studyMelanocytic nevus occurs in 4% of patients11

  • human studyRespiratory tract infection occurs in 4% of patients11

  • human studySomnolence occurs in 2% of patients11

  • human studyNonacute porphyria occurs in 2% of patients11

  • human studySkin irritation occurs in 2% of patients11

  • animalNo adverse developmental effects observed in rats4

  • animalIn animal reproductive and development toxicity studies, no adverse developmental effects were observed with administration during organogenesis to pregnant rats at SC doses up to 12 times the maximum recommended human dose (MRHD)11

  • animalRepeated Dose Chronic Toxicity Study in PVG/C Arc Black Hooded Rats Treated With Afamelanotide 16 mg Implant and Narrow-Band Ultraviolet B (NB-UVB) Light Irradiation16

  • animalNinety Day Repeated Dose Subcutaneous Toxicity Study in the Rat16

  • animal10-Month Subcutaneous Toxicity Study of Afamelanotide Implants in Dogs With 1-Month Recovery16

  • animalReproductive Toxicology Studies conducted16

  • animalGenetic Toxicology Studies conducted16

  • animalCarcinogenicity studies conducted16

  • animalReproductive and Developmental Toxicology Studies conducted16

  • expert opinionNo drug interaction studies were conducted with afamelanotide8

  • expert opinionThe effect of renal or hepatic impairment on the pharmacokinetics of afamelanotide is unknown8

  • expert opinionCommon adverse events were headache, fatigue, and nausea22

  • expert opinionAfamelanotide is well tolerated22

  • expert opinionMelanotan I leads to the activation of dysplastic nevi24

  • expert opinionMelanotan I and bleaching creams, which may possibly contain mercury, are dangerous24

What people use it for

Based on 15 human trial findings, 2 human study findings and 15 expert opinion findings.

  • human trialAfamelanotide is a medication used to prevent phototoxicity and to reduce pain from light exposure for people with erythropoietic protoporphyria3

  • human trialIn the European Union, afamelanotide is indicated for the prevention of phototoxicity in adults with erythropoietic protoporphyria3

  • human trialIn the United States, afamelanotide is indicated for increasing pain-free light exposure in adults with a history of reactions to light (phototoxicity) from erythropoietic protoporphyria3

  • human trialAfamelanotide was evaluated for treating erythropoietic protoporphyria, a severe photodermatosis associated with acute phototoxicity5

  • human trialSCENESSE is approved to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)8

  • human trialSCENESSE is a melanocortin 1 receptor (MC1-R) agonist indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)9

  • human trialSCENESSE is a melanocortin 1 receptor (MC1-R) agonist indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)10

  • human trialMaintain sun and light protection measures during treatment with SCENESSE to prevent phototoxic reactions related to EPP10

Show the remaining 24

  • human trialAfamelanotide is indicated for prevention of phototoxicity and anaphylactoid reactions in adults with erythropoietic protoporphyria (EPP)11

  • human trialAfamelanotide (Scenesse) is the only FDA-approved drug in the Melanotan class, cleared in 2019 specifically for adults with erythropoietic protoporphyria12

  • human trialThe European Medicines Agency approved afamelanotide in 201412

  • human trialAs of April 2026, no indication exists for cosmetic tanning12

  • human trialFDA-approved to increase pain-free sunlight exposure in adult patients with erythropoietic protoporphyria15

  • human trialApproved indication: Adult patients with erythropoietic protoporphyria16

  • human trialApproved in the EU for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP)18

  • human studyMelanocortin 1 receptor (MC1-R) agonist used to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria4

  • human studySince 2016 afamelanotide has been especially applied to treat cases of erythropoietic porphyria (EPP)13

  • expert opinionAfamelanotide is FDA-approved for treatment of EPP2

  • expert opinionImplantation by a health care professional is required2

  • expert opinionDesignated an orphan drug by FDA for treatment of erythropoietic protoporphyria4

  • expert opinionAfamelanotide is used for prevention of phototoxicity in erythropoietic protoporphyria6

  • expert opinionErythropoietic protoporphyria (EPP) is a metabolic disorder that leads to the accumulation of protoporphyrin7

  • expert opinionEPP presents with painful photosensitivity observed since early childhood13

  • expert opinionAfamelanotide is a therapeutic option available for treatment of vitiligo14

  • expert opinionAfamelanotide is reviewed among available treatments for vitiligo including phototherapy, cyclosporine, phosphodiesterase 4 inhibitors, and JAK inhibitors14

  • expert opinionVitiligo is a common disorder of depigmentation caused by the progressive destruction of melanocytes that affects the skin, hair, and mucous membranes19

  • expert opinionThe melanocortin system is a promising therapeutic target for treating various metabolic disorders such as obesity and cachexia, as well as anorexia nervosa20

  • expert opinionVitiligo is an acquired hypopigmentation of the skin due to a progressive selective loss of melanocytes21

  • expert opinionAfamelanotide is the first effective approved medical treatment for EPP22

  • expert opinionAfamelanotide is a symptomatic treatment for EPP; PPIX levels remain the same and it is unlikely to protect against PPIX-mediated liver damage22

  • expert opinionAfamelanotide is a new approach developed as a promising treatment for acne vulgaris23

  • expert opinionAfamelanotide is a prescription drug for the orphan disease erythropoietic protoporphyria24

Other findings

Based on 1 human trial finding and 6 expert opinion findings.

  • human trialInitial U.S. Approval: 20199

  • expert opinionAfamelanotide was developed in the early 1980s by Victor Hruby and Mac Hadley's group at the University of Arizona12

  • expert opinionLarger scale studies needed to confirm efficacy beyond erythropoietic protoporphyria15

  • expert opinionFurther research needed on safety, efficacy, and optimal dosing for pediatric patients15

  • expert opinionVitiligo has a prevalence of 1-2%21

  • expert opinionAfamelanotide was recommended for approval by the European Medicines Agency in December 201422

  • expert opinionStructurally related α-MSH derivatives are available via the internet24

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Contested

Sources disagree on whether afamelanotide protects against EPP-related liver damage.

A tier-3 review (Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria) states afamelanotide is only symptomatic — PPIX levels remain unchanged and it is unlikely to protect against PPIX-mediated liver damage — whereas a tier-1 review (Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria) reports a dose-dependent protective effect from EPP-related liver damage and notes animal-model evidence that MSHs protect the liver.

Contested

Reported half-life values span from 30 minutes to about 15 hours, and the sources describe them under different conditions.

Regulatory and database sources give an elimination half-life of roughly 15 hours (Scenesse (afamelanotide) dosing, indications, interactions, adverse effects, and more; Afamelanotide Acetate Monograph for Professionals - Drugs.com; FDA News: Issue 29, October 2019). The FDA News: Issue 29, October 2019 briefing specifies that this is an "apparent" half-life measured after subcutaneous administration of the controlled-release implant, which reflects slow release from the implant. By contrast, the Afamelanotide - Wikipedia entry lists an elimination half-life of 30 minutes without any such qualifier, so the figures may describe release-limited versus intrinsic kinetics rather than a straightforward disagreement.

Other

An AUC value is inconsistently reported across regulatory sources.

FDA News: Issue 29, October 2019 reports AUC0-inf of 138.9 ± 42.6 hr·ng/mL, while Scenesse (afamelanotide) dosing, indications, interactions, adverse effects, and more lists AUC as 42.6 hr·ng/mL — the latter appears to correspond to the standard deviation rather than the mean AUC, indicating a likely reporting inconsistency.

Contested

RCT results on photosensitivity/sun exposure are inconsistent.

Within one review (Afamelanotide - an overview | ScienceDirect Topics), of three RCTs: one found a benefit (about 8 additional pain-free sunlight minutes/day), one found no difference versus placebo, and one reported increased sun exposure with treatment — indicating variable measured photosensitivity outcomes.

Limited evidence

Efficacy beyond EPP rests on smaller or lower-tier studies.

Uses in vitiligo, acne vulgaris, Hailey-Hailey disease, solar urticaria, and polymorphic light eruption are supported by RCTs or smaller studies (Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications.), but several are drawn from tier-3 reviews (Vitiligo: Pathogenesis and New and Emerging Treatments., From pathogenesis of acne vulgaris to anti-acne agents.), and Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. explicitly notes larger studies are needed to confirm efficacy beyond EPP and pediatric data are lacking.

Single source

Acute ischemic stroke use rests on a single small study.

The claim that afamelanotide is safe, well tolerated, and associated with recovery/radiological improvement in acute ischemic stroke comes from one small observational study (A feasibility and safety study of afamelanotide in acute stroke patients) with a small sample.

Limited evidence

Claim that real-world effectiveness exceeds trial data is expert opinion.

The assertion that afamelanotide is much more effective in clinical practice than in clinical trials, and that the 60-day dosing interval was not based on effectiveness studies, comes from a single tier-3 expert-opinion review (Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria).

Limited evidence

Metabolism and special-population pharmacokinetics are not characterized.

Per FDA News: Issue 29, October 2019, afamelanotide's metabolic profile has not been fully characterized, no drug-interaction studies were conducted, and effects of renal or hepatic impairment on its pharmacokinetics are unknown.

Using it with other compounds

Check a stack
  • BremelanotideSame mechanism

    Worth caution

    Both are melanocortin-receptor agonists signaling via Gs/adenylyl cyclase cAMP. Bremelanotide targets central MC4R/MC3R for sexual arousal and has only low MC1R activity, so it isn't redundant for pigmentation " but because both engage the melanocortin system you should understand that combining them broadens melanocortin activation (bremelanotide can cause some skin darkening, and afamelanotide the pigment effect), and side effects like nausea or flushing may overlap.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    While both peptides do engage cAMP/PKA signaling through melanocortin receptors, they target fundamentally different receptors with distinct physiological outcomes. Afamelanotide is an MC1R agonist producing peripheral pigmentation effects, while bremelanotide primarily targets central MC4R/MC3R for sexual arousal modulation. The proposed relationship claims 'same_mechanism' based on shared cAMP_PKA signaling, but this is a superficial commonality—the actual mechanisms differ substantially in receptor selectivity, anatomical site of action (peripheral vs. central), downstream pathway engagement (MITF/tyrosinase vs. dopaminergic/serotonergic modulation), and clinical effects. 'Same mechanism' typically implies equivalent or overlapping therapeutic pathways; these peptides operate through distinct melanocortin receptor subtypes producing unrelated primary effects. The explanation acknowledges they are 'not redundant' and have different targets, which contradicts the 'same_mechanism' classification. Shared second-messenger signaling (cAMP) is insufficient to justify 'same_mechanism' when the upstream receptors and downstream consequences are distinct.

    Shares cAMP PKA

  • KPVComplementary

    No documented conflict

    KPV is the C-terminal tripeptide fragment of alpha-MSH and shares afamelanotide's anti-inflammatory arm, but it works mainly by dampening NF- fB-driven cytokines rather than by pigmentation. So a user pairing them would get overlapping anti-inflammatory action from a related molecular family while afamelanotide provides the distinct photoprotection/pigment benefit " understand the anti-inflammatory effects converge and are not strictly additive.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides demonstrate anti-inflammatory activity through their mechanism descriptions. Afamelanotide shows anti-inflammatory activity via cAMP/PKA and proposed Akt/mTORC1 attenuation pathways. KPV shows anti-inflammatory activity primarily through NF-κB suppression (IκBα stabilization, IKK inhibition, p65RelA nuclear import blockade) and MAPK signaling. While their mechanisms differ substantially—afamelanotide works through MC1R agonism and melanogenic pathways, KPV works through NF-κB and MAPK modulation—both peptides are documented to produce anti-inflammatory effects. The explanation correctly identifies that KPV is a C-terminal fragment of α-MSH (the natural hormone afamelanotide mimics) and accurately describes their distinct primary mechanisms (pigmentation vs. cytokine dampening) while sharing an anti-inflammatory dimension. The characterization as 'complementary' with overlapping rather than strictly additive anti-inflammatory action is reasonable given their different mechanistic pathways converging on inflammation resolution.

    Shares anti inflammatory

  • Melanotan IISame mechanism

    Worth caution

    Both are alpha-MSH-derived melanocortin agonists that drive eumelanin synthesis and tanning through MC1R and the cAMP/PKA/CREB cascade. Afamelanotide is MC1R-selective while Melanotan II also hits MC3R/MC4R/MC5R (adding appetite suppression and sexual/erectile effects). Stacking them for pigmentation is redundant and would layer melanocortin over-activation; pick one for the pigment goal rather than combining.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish the proposed relationship. They share the cAMP_PKA dimension: Afamelanotide targets MC1R as an agonist activating adenylyl cyclase/cAMP pathways and MITF pathway for eumelanin synthesis. Melanotan II similarly activates MC1R through adenylyl cyclase/cAMP elevation and the cAMP-PKA-CREB cascade for tyrosinase upregulation and eumelanin synthesis. Both are described as alpha-MSH-derived melanocortin agonists. The key mechanistic difference (Melanotan II's additional MC3R/MC4R/MC5R activation driving appetite suppression and sexual effects) is accurately noted and does not contradict the shared cAMP_PKA dimension for pigmentation. The explanation correctly identifies that both converge on the same MC1R-cAMP-PKA-eumelanin pathway for tanning, making them mechanistically similar in their primary pigmentation effect, even though Melanotan II has broader receptor selectivity.

    Shares cAMP PKA

  • Alpha-MSHSame mechanism

    Worth caution

    Afamelanotide is a synthetic, longer-lasting analog of alpha-MSH and hits the exact same melanocortin-1 receptor (MC1R) through the same cAMP/PKA pigment-signaling cascade. Stacking them is redundant, not additive " you'd be activating the same receptor twice, and alpha-MSH's broader receptor spread (MC3R/MC4R/MC5R) just adds off-target effects (appetite, sexual) without improving the photoprotection or pigmentation goal. Choose one rather than combining.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanism descriptions clearly establish that both peptides target MC1R and activate the adenylyl cyclase/cAMP/PKA pathway. Afamelanotide is explicitly described as 'a lab-made, longer-lasting version of a natural hormone (α-MSH)' and the explanation correctly identifies that both share MC1R agonism and cAMP/PKA signaling. Both peptides are tagged with anti_inflammatory and cAMP_PKA. The proposed relationship accurately reflects that they operate through the same primary mechanism (MC1R→cAMP/PKA) for their shared anti-inflammatory and pigmentation effects, making them mechanistically equivalent at their core target despite alpha-MSH's additional receptor activity at MC3R/MC4R/MC5R.

    Shares anti inflammatory · cAMP PKA

Safety and side effects

Safety and Tolerability

Afamelanotide is generally described as well tolerated, with adverse events mostly mild. Serious adverse events in the pivotal trials were not thought to be related to the study drug, and no drug-related serious adverse events were reported in the phase III trial.

Common Adverse Reactions

The most common adverse reactions (incidence >2%) reported include:

  • Implant site reaction (~21%)
  • Nausea (~19%)
  • Headache (~20%) (reported in some sources)
  • Oropharyngeal pain (~7%)
  • Fatigue (~6%)
  • Skin hyperpigmentation (~4%)
  • Dizziness (~4%)
  • Melanocytic nevus (~4%)
  • Respiratory tract infection (~4%)
  • Somnolence (~2%)
  • Non-acute porphyria (~2%)
  • Skin irritation (~2%)

Other reported adverse effects include back pain, upper respiratory tract infections, decreased appetite, migraine, and weakness.

Skin Pigmentation and Nevi Monitoring

Because of its pharmacological mechanism, afamelanotide may induce darkening of pre-existing nevi and ephelides and cause generalized increased skin pigmentation — diffuse hyperpigmentation is experienced by almost all patients. A regular full-body skin examination twice yearly (every 6 months) is recommended to monitor pre-existing nevi and any new skin pigmentary lesions.

Serious Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported — uncommon but potentially serious. Patients are advised to be monitored for 30 minutes after administration.

Precautions and Unknowns

  • No drug interaction studies were conducted.
  • The effect of renal or hepatic impairment on afamelanotide pharmacokinetics is unknown.
  • The metabolic profile has not been fully characterized (possible hydrolysis).
  • Patients should maintain sun and light protection measures during treatment to prevent EPP-related phototoxic reactions.
  • Pediatric safety and efficacy data are lacking.

Preclinical Safety

Animal reproductive and developmental toxicity studies showed no adverse developmental effects with dosing during organogenesis in pregnant rats at subcutaneous doses up to 12 times the maximum recommended human dose. Preclinical work included repeated-dose chronic toxicity in rats (with NB-UVB irradiation), a 90-day repeated-dose SC toxicity study in rats, a 10-month SC toxicity study in dogs with 1-month recovery, plus reproductive, genetic, and carcinogenicity studies.

Note on Unregulated Analogues

Structurally related α-MSH derivatives (e.g., Melanotan I) are available via the internet; Melanotan I can lead to activation of dysplastic nevi, and such products (along with bleaching creams possibly containing mercury) have been described as dangerous.

Reconstitution and handling

Formulation and Storage

Afamelanotide is not supplied as a reconstitutable lyophilized powder for self-preparation. It is formulated as a bioresorbable subcutaneous controlled-release implant containing 16 mg of afamelanotide. The implant must be stored at 2–8°C and is administered by a healthcare professional.

Dosing

  • Recommended dosage: a single 16 mg implant inserted subcutaneously every 2 months (60 days).
  • Note: the 60-day dosing interval was reportedly not based on effectiveness studies (expert-opinion observation).

Insertion Technique

The implant is placed 3–4 cm above the anterior supra-iliac crest, inserted at a 30–45° angle and advanced approximately 2 cm into the subcutaneous layer. Insertion is performed by a licensed healthcare professional.

In the pivotal trials, EU patients received 5 implants total and U.S. patients received 3 implants total, dosed every 60 days.

Post-Administration Monitoring

Patients should be monitored for 30 minutes after administration due to the risk of serious hypersensitivity reactions. A full-body skin examination every 6 months is recommended to monitor nevi and pigmentary lesions. Sun and light protection measures should be maintained throughout treatment.

Pharmacokinetics (Implant)

Following a single subcutaneous implant: mean Cmax ~3.7 ± 1.3 ng/mL; AUC0-inf ~138.9 ± 42.6 hr·ng/mL (one regulatory source reported 42.6 hr·ng/mL, likely a reporting inconsistency corresponding to the standard deviation); median Tmax ~36 hours; apparent half-life ~15 hours; last measurable plasma concentration at ~96 hours in most patients. High variability in plasma concentrations was observed. A 30-day PK study of CUV1647 release from 10- and 16-mg bioresorbable implants was conducted in rats.

Sources

Ordered by evidence quality — the strongest first.

  1. A feasibility and safety study of afamelanotide in acute stroke patients(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  2. Afamelanotide - an overview | ScienceDirect Topics(opens in a new tab)
    Tier 1Web · sciencedirect.com
  3. Afamelanotide - Wikipedia(opens in a new tab)
    Tier 1Web · en.wikipedia.org
  4. Afamelanotide Acetate Monograph for Professionals - Drugs.com(opens in a new tab)
    Tier 1Web · drugs.com
  5. Afamelanotide for Erythropoietic Protoporphyria(opens in a new tab)
    Tier 1Web · nejm.org
  6. Afamelanotide for prevention of phototoxicity in erythropoietic ...(opens in a new tab)
    Tier 1Web · tandfonline.com
  7. Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria(opens in a new tab)
    Tier 1Web · mdpi.com
  8. FDA News: Issue 29, October 2019(opens in a new tab)
    Tier 1Web · ascpt.org
  9. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SCENESSE safely and effectively. See full prescribing information for SCENESSE. SCENESSE (afamelanotide) implant, for subcutaneous use Initial U.S. Approval: 2019 ----------------------------INDICATIONS AND USAGE--------------------------- SCENESSE is a melanocortin 1 receptor (MC1-R) agonist indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). (1) -----------------------DOSAGE AND ADMINISTRATION----------------------- SCENESSE should be administered by a healthcare professional who is proficient in the subcutaneous implantation procedure and has completed training prior to administration. (2.1) Insert a single implant, containing 16 mg of afamelanotide, using an SFM Implantation Cannula or other implantation devices that have been determined by the manufacturer to be suitable for implantation of SCENESSE. (2) Administer SCENESSE subcutaneously every 2 months (2.1).(opens in a new tab)
    Tier 1Web · scenesse.com
  10. Label: SCENESSE- afamelanotide implant(opens in a new tab)
    Tier 1Web · dailymed.nlm.nih.gov
  11. Scenesse (afamelanotide) dosing, indications, interactions, adverse effects, and more(opens in a new tab)
    Tier 1Web · reference.medscape.com
  12. Superpower(opens in a new tab)
    Tier 1Web · superpower.com
  13. Afamelanotide in protoporphyria and other skin diseases: a review.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  14. Vitiligo: Pathogenesis and New and Emerging Treatments.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  15. Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  16. 210797Orig1s000 - accessdata.fda.gov(opens in a new tab)
    Tier 1Web · accessdata.fda.gov · 2019
  17. [Porphyrias-what is verified?].(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2018
  18. Afamelanotide: A Review in Erythropoietic Protoporphyria.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2016
  19. Treatment Advances in Vitiligo: An Updated Review.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  20. Targeting the central melanocortin system for the treatment of metabolic disorders.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  21. Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  22. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria(opens in a new tab)
    Tier 3Web · doi.org · 2021
  23. From pathogenesis of acne vulgaris to anti-acne agents.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  24. [Undesirable pigmentation].(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2015
  25. Phototherapy for Vitiligo.(opens in a new tab)
    Tier 4PubMed · pubmed.ncbi.nlm.nih.gov · 2020